Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to $1.5 million.

  • Enanta Pharmaceuticals' Capital Expenditures fell 8371.13% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.9 million, marking a year-over-year decrease of 2814.8%. This contributed to the annual value of $12.9 million for FY2025, which is 2814.8% down from last year.
  • As of Q3 2025, Enanta Pharmaceuticals' Capital Expenditures stood at $1.5 million, which was down 8371.13% from $155000.0 recorded in Q2 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Capital Expenditures peaked at $9.0 million during Q3 2024, and registered a low of $33000.0 during Q3 2021.
  • In the last 5 years, Enanta Pharmaceuticals' Capital Expenditures had a median value of $1.4 million in 2022 and averaged $2.2 million.
  • In the last 5 years, Enanta Pharmaceuticals' Capital Expenditures surged by 425454.55% in 2022 and then plummeted by 9750.2% in 2025.
  • Enanta Pharmaceuticals' Capital Expenditures (Quarter) stood at $363000.0 in 2021, then skyrocketed by 769.42% to $3.2 million in 2022, then tumbled by 75.06% to $787000.0 in 2023, then surged by 1011.18% to $8.7 million in 2024, then tumbled by 83.33% to $1.5 million in 2025.
  • Its Capital Expenditures stands at $1.5 million for Q3 2025, versus $155000.0 for Q2 2025 and $2.5 million for Q1 2025.